Brief: Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications
21/04/2025 12:50
April 21 (Reuters) - Immunovant Inc IMVT.O: IMMUNOVANT ANNOUNCES NEXT PHASE OF GROWTH WITH ROIVANT INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND ADDITIONAL INDICATIONS SJÖGREN’S DISEASE (SJD) AND CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) FOR IMVT-1402 IMMUNOVANT INC - ERIC VENKER APPOINTED AS CEO OF IMMUNOVANT IMMUNOVANT INC - TIAGO GIRAO APPOINTED AS CFO OF IMMUNOVANT IMMUNOVANT INC - IND CLEARED FOR IMVT-1402 IN SJD, STUDY TO INITIATE SUMMER 2025 IMMUNOVANT INC - CURRENT CASH BALANCE PROVIDES RUNWAY THROUGH GRAVES’ DISEASE READOUT IN 2027 Source text: ID:nGNX5fPccv Further company coverage: IMVT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple